Suppr超能文献

重症监护和后续医疗保健的成本和成本效益:一项多中心前瞻性研究。

Costs and Cost-Utility of Critical Care and Subsequent Health Care: A Multicenter Prospective Study.

机构信息

Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Centre for Health and Social Economics CHESS, National Institute for Health and Welfare, Helsinki, Finland.

出版信息

Crit Care Med. 2020 May;48(5):e345-e355. doi: 10.1097/CCM.0000000000004210.

Abstract

OBJECTIVES

The number of critical care survivors is growing, but their long-term outcomes and resource use are poorly characterized. Estimating the cost-utility of critical care is necessary to ensure reasonable use of resources. The objective of this study was to analyze the long-term resource use and costs, and to estimate the cost-utility, of critical care.

DESIGN

Prospective observational study.

SETTING

Seventeen ICUs providing critical care to 85% of the Finnish adult population.

PATIENTS

Adult patients admitted to any of 17 Finnish ICUs from September 2011 to February 2012, enrolled in the Finnish Acute Kidney Injury (FINNAKI) study, and matched hospitalized controls from the same time period.

INTERVENTIONS

None.

MEASUREMENTS AND MAIN RESULTS

We primarily assessed total 3-year healthcare costs per quality-adjusted life-years at 3 years. We also estimated predicted life-time quality-adjusted life-years and described resource use and costs. The costing year was 2016. Of 2,869 patients, 1,839 (64.1%) survived the 3-year follow-up period. During the first year, 1,290 of 2,212 (58.3%) index episode survivors were rehospitalized. Median (interquartile range) 3-year cumulative costs per patient were $49,200 ($30,000-$85,700). ICU costs constituted 21.4% of the total costs during the 3-year follow-up. Compared with matched hospital controls, costs of the critically ill remained higher throughout the follow-up. Estimated total mean (95% CI) 3-year costs per 3-year quality-adjusted life-years were $46,000 ($44,700-$48,500) and per predicted life-time quality-adjusted life-years $8,460 ($8,060-8,870). Three-year costs per 3-year quality-adjusted life-years were $61,100 ($57,900-$64,400) for those with an estimated risk of in-hospital death exceeding 15% (based on the Simplified Acute Physiology Score II).

CONCLUSIONS

Healthcare resource use was substantial after critical care and remained higher compared with matched hospital controls. Estimated cost-utility of critical care in Finland was of high value.

摘要

目的

重症监护幸存者的数量不断增加,但他们的长期预后和资源利用情况描述不佳。评估重症监护的成本效益是确保资源合理利用的必要条件。本研究的目的是分析重症监护的长期资源利用和成本,并估计其成本效益。

设计

前瞻性观察性研究。

地点

为芬兰 85%的成年人口提供重症监护的 17 个 ICU。

患者

2011 年 9 月至 2012 年 2 月期间入住芬兰任何一家 17 家 ICU 的成年患者,参加芬兰急性肾损伤(FINNAKI)研究,并与同期同一时期住院的对照患者相匹配。

干预措施

无。

测量和主要结果

我们主要评估了 3 年的总医疗保健成本,每 3 年的质量调整生命年为 1 个单位。我们还估计了预测的终身质量调整生命年,并描述了资源的使用和成本。计价年为 2016 年。在 2869 名患者中,有 1839 名(64.1%)在 3 年随访期后存活。在第一年,2212 名指数期幸存者中有 1290 名(58.3%)再次住院。中位数(四分位距)每名患者 3 年累积成本为 49200 美元(30000-85700 美元)。ICU 成本占 3 年随访期间总费用的 21.4%。与匹配的医院对照相比,危重病患者的成本在整个随访期间仍然较高。估计的总平均(95%CI)每 3 年质量调整生命年的 3 年总成本为 46000 美元(44700-48500 美元)和每 3 年质量调整生命年的预计终身总成本为 8460 美元(8060-8870 美元)。预计风险超过 15%(基于简化急性生理学评分 II)的住院死亡风险的患者,每 3 年质量调整生命年的 3 年成本为 61100 美元(57900-64400 美元)。

结论

重症监护后医疗资源的使用量很大,与匹配的医院对照相比仍然较高。芬兰重症监护的成本效益估计具有很高的价值。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验